About Biomarck

We Are Advancing Therapies

For Patients in Need

Novel Anti-MARCKS Platform

Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, supporting safety and efficacy in these potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis. In oncology, inhibiting MARCKS with our peptides blocks migration of NSCLC cells in vitro and inhibits metastasis in animal models of NSCLC.

We Bring Expertise in Research and New Drug Development

Biomarck has assembled a management team, Board of Directors and Scientific Advisory Board with extensive experience in new drug development, clinical practice, and clinical research, to rapidly advance a pipeline of MARKS protein inhibitors for multiple indications.

Management Team

Graham Lumsden, BVM&S, MRCVS

President, CEO, and Executive Director

Alistair Wheeler, MB BS, MFPM

Chief Medical Officer

Lawrence B. Florin, MBA

Clinical Operations Consultant

Chris Lehman, MBA

Chief Financial Officer / Advisor

Board of Directors

Rajin Ahuja

Executive Chairman of the Board

Andrew Davis

Vice Chairman

Thomas H. Roberg

Board Observer, Co-Founder

Graham Lumsden, BVM&S, MRCVS

President, CEO, and Executive Director

Our Partners Lead the Way in Bringing Therapies to Patients in Need

North Carolina State University

Biomarck has a long and rewarding history of collaboration with the laboratory of Kenneth Adler, Ph.D., a Professor of Molecular Biomedical Sciences at North Carolina State University. When Dr. Adler began studying MARCKS in the late 1990’s, there were no known ways to inhibit the biological function of MARCKS protein and its role in several biological processes was merely correlative. Dr. Adler’s laboratory developed the MANS peptide, which was shown to block MARCKS function in a variety of cell types, including airway epithelial cells and inflammatory cells. The MANS peptide is the basis for the development of BIO-11006. Dr. Adler has been the recipient of continuous long-term research funding from the National Institute of Health (NIH), and in 2004 received a MERIT award from NHLBI. He has served as Chair of the NIH Lung Biology and Pathology and Lung Cellular and Molecular Immunology study sections.

National Institutes of Health (NIH)

Biomarck has been awarded a succession of grants from the NIH and related entities, including a Phase I SBIR Grant for $100,000 in 2003, a Phase II SBIR Grant for $1,228,000 in 2004, a Phase III SBIR Grant for $2,990,000 in 2006, a SBIR Grant for $3,000,000 in 2014, and a STTR Grant for $201,503 in 2014.

Live Like Bella Foundation

Biomarck has a limited compassionate use program in place that has supported children with difficult to treat cancers, such as rhabdomyosarcoma and neuroblastoma, as part of a collaboration with the Live Like Bella Foundation. To learn more, visit our page on Expanded Access.